#Guangzhu

Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis. https://t.co/42gDXziDI9 Important for ARMANI2👇🏻 Ready to start in 2026

🎧 New @myESMO GI podcast! Get the latest insights on upper GI cancers 🔑 updates on oesophageal & #gastric cancer from the #ESMOCongress 2025 @FilippoPietran4 @tfleitask 🔈Listen now: 🔗 https://t.co/haOKpDDjr0 🔗 https://t.co/7M3recvWqw #Oncology #GIcancer #CancerResearch

🔬 Gastrointestinal Cancers Genomic-guided adjuvant therapies, immune checkpoint combos, and novel targeted agents — all in one session. Watch now: https://t.co/lN31Dt7EPK #ESMO25 #ESMOWebinars

In #dMMR metastatic #crcsm, first-line dual #IO outperformed both #PD1 monotherapy and chemotherapy with manageable toxicity. Benefits were strongest in #left-sided or #BRAF mutant tumors #GIonc @FilippoPietran4 @susanebates @gbanna74 @PasRescigno https://t.co/YKpxfW1NPc

Sharing our work in the spatial biology of HER2+ gastric cancer @GUTJournal_BMJ. Figuring out and targeting the tumor microenvironment is an exciting time for cancer therapeutics. @FilippoPietran4 @josephjzhao @KoheiShitara

✨ 𝗠𝗶𝘀𝘀𝗲𝗱 𝗘𝗦𝗠𝗢 𝗚𝗜 𝗚𝗿𝗮𝗻𝗱 𝗥𝗼𝘂𝗻𝗱𝘀? It wasn’t just a session — it was 💬 connection, 🤝 mentorship, and 🌍 the pulse of global oncology in one evening. From HER2 to ctDNA and next-gen immunotherapy, the biggest minds broke down what’s next in GI oncology.

Registration is open for the #ESMO25 Congress Highlights Webinar on #GastrointestinalCancers! 🎓 Expert insights, clinical relevance, live Q&A ✅ Free for all ESMO account holders #ESMOWebinars 🔗 https://t.co/hAwmIFGzXs

Risk of disease progression in first-line metastatic colorectal cancer therapy to guide disease reassessments―analysis of 11 trials by AIO and GONO☆ - Annals of Oncology https://t.co/vxIzpVEHM7 How many times your patients were not able to book a scan? Risk adapted guidance !

𝗣𝗿𝗲𝗽𝗮𝗿𝗶𝗻𝗴 𝗧𝗿𝗮𝗶𝗻𝗲𝗲𝘀 𝗳𝗼𝗿 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗨𝗻𝗰𝗲𝗿𝘁𝗮𝗶𝗻𝘁𝘆 Uncertainty is ubiquitous in medical practice yet is often viewed as a regrettable phenomenon to be tolerated or eradicated. To prepare trainees for practice, teachers need to reframe uncertainty

Reconnected with my mentor @YJanjigianMD at #ESMO25, always inspiring. Six presentations this Congress, plus multiple panel roles. (Will remember this next time I complain about making one PPT) We Were also excited to host @oncodaily GI Grand Rounds with a fantastic expert panel

📢 #ESMO25 concomitant paper: results from the phase III trial of 177Lu-Dotatate vs high-dose octreotide for advanced Grade 1-2 GEP-NETs https://t.co/Hnn6tNJVAb

🆕article in press: #ESMO25 editorial article “The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors” by @RachelRiechelm2 https://t.co/PWJTzwJKQU

Patient-reported outcomes with paclitaxel and ramucirumab switch

RT @VJOncology: Lovely as ever to speak with @FilippoPietran4 (@IstTumori) at #ESMO25, who updated us on the DESTINY-Gastric04 trial, discu…

🙏🏻 corresponding author @ChrisCannMD @FoxChaseCancer

📢 #ESMO25 | #NETs COMPETE trial: ¹⁷⁷Lu-edotreotide vs everolimus in G1–2 GEP-NETs 🧩 mPFS 23.9 vs 14.1 mo | HR 0.67 (95% CI 0.48–0.95); p=0.022 🧩 ORR 22% vs 4% (p<0.0001) ⚕️ Drug-related discontinuations: 2% vs 15% 💡 ¹⁷⁷Lu-edotreotide outperforms everolimus, safer ✅

Amazing results on Belzutifan in #pheochromocytoma #paraganglioma led by Camilo Jimenez + authors @JaydiDelRivero @Ja_Capdevila @GCarboneroLab mPFS 22 mo Overall disease control rate 85% Median time to response 11 mo Median duration response 20mo #ESMO25 #NEJM

Please don’t miss the AMAZING Editorial by dr Cathy Eng and team putting in context the results of PARERE trial published in @Annals_Oncology !! Amazingly written and really helpful for all clinicians! https://t.co/cbOd0sJljy

📢 #ESMO25 concomitant paper: results from the phase III trial of 177Lu-Dotatate vs high-dose octreotide for advanced Grade 1-2 GEP-NETs https://t.co/Hnn6tNJnKD